Search

Researchers at the University of South Bohemia have identified potential bioactive phytochemicals, Genostrychnine and Chelidonine, that inhibit the kinase activity of platelet-derived growth factor receptor beta (PDGFRb), a receptor tyrosine kinase implicated in various cancers. These compounds were discovered through a structure-based approach using drug discovery parameters and molecular dynamics simulation studies. The findings suggest that these small molecules could be valuable tools in studying PDGFRb properties and developing therapies for cancer and related diseases. [Extracted from the article]

A report by Boehringer Ingelheim Pharma GmbH & Co. KG discusses the findings on BI 836880, a VEGF/Ang-2 inhibitor. The research focuses on a comprehensive biomarker and modeling approach to support dose finding for BI 836880, a humanized bispecific nanobody that binds to and blocks VEGF and Ang-2. The study conducted two Phase I dose-escalation studies to assess the drug's efficacy in adults with advanced solid tumors refractory to standard therapy. The research concludes that BI 836880 720 mg q3w is a biologically relevant monotherapy dose schedule. [Extracted from the article]

The article discusses a study that characterizes the distribution of fms-like tyrosine kinase 3 (FLT3) and other neuronal proteins in the brain using an alkaline phosphatase immunolabeling method. The research reveals a neuron-selective expression pattern of FLT3 in the cerebellum of both mice and humans, showing changes in protein levels and distribution during brain development. The study also demonstrates the effectiveness of the alkaline phosphatase method in labeling other neuronal proteins like Kir2.1 and PSD95 in various brain tissue samples. This work provides valuable insights into the localization of neuronal proteins in the brain, particularly FLT3, and sets the stage for further investigations into their roles in brain development and function. [Extracted from the article]

Researchers have submitted a patent application titled "Internalizing Binding Molecules" to address fibrosis, a condition that affects various organs and leads to loss of function. The patent focuses on developing therapeutic molecules that target fibrogenic effector cells, such as those found in liver, lung, kidney fibrosis, and certain types of tumors. By specifically binding to receptors expressed on these cells, the molecules aim to reduce fibrotic activity and potentially reverse the fibrotic process. The patent application was filed by LinXis B.V. and inventors from Amsterdam, Netherlands. [Extracted from the article]

A recent study from Baylor University College of Medicine in Houston, Texas, explores the potential of gene therapy in treating neovascular diseases. The research focuses on developing disease-targeted gene therapy to address concerns about adverse side effects of current treatments. The study specifically investigates the use of adeno-associated virus (AAV) delivery of a novel anti-Scg3 antibody to suppress choroidal neovascularization, showing promising results in inhibiting pathological angiogenesis without affecting healthy vessels. This research, supported by the U.S. Department of Health & Human Services, suggests that AAV-anti-Scg3 could be a safer alternative to current treatments with equivalent efficacy. [Extracted from the article]

A study conducted at Sun Yat-sen University in Guangdong, China, focused on the clinical utility of circulating tumor DNA (ctDNA) for detecting lung cancer mutations using targeted next-generation sequencing. The research involved 60 patients with non-small cell lung cancer (NSCLC) and found a 75.47% concordance rate between tissue DNA (tDNA) and ctDNA samples, with epidermal growth factor receptor (EGFR) mutations being the most common. The study concluded that identifying ctDNA mutations through targeted sequencing in plasma is feasible and valuable for NSCLC patients when tumor tissue sampling is inadequate or impossible. [Extracted from the article]

Monash University researchers conducted a study on receptor protein-tyrosine kinases, focusing on the role of VEGF-dependent MEK1/2 signaling and angiogenesis factors SOX7 and SOX17 in testicular vascularization. The study found that MEK1/2 signaling is crucial for vasculature development, while FGF signaling through MEK1/2 regulates Sertoli cell organization in the developing mouse testis. This research sheds light on the importance of VEGF-dependent signaling in promoting vasculature and the regulation of Sertoli cell organization in testicular development. [Extracted from the article]

Researchers have submitted a patent application for a method of treating cancer using a Raf inhibitor, targeting the MAPK/ERK pathway. The patent application outlines various embodiments for administering the inhibitor to patients with different types of cancer, including solid tumors and metastatic cancers. The inventors aim to provide a novel therapeutic approach for patients in need of cancer treatment, focusing on specific molecular pathways involved in cancer progression. [Extracted from the article]

Researchers from George Washington University School of Medicine and Health Sciences conducted a study on insulin receptors in the subfornical organ (SFO) of mice, a brain region involved in cardiovascular and metabolic regulation. They found that SFO neurons, including excitatory and inhibitory types, were the primary site of insulin receptor expression, with some expression also detected in astrocytes. Additionally, SFO angiotensin type 1a receptor neurons were found to express insulin receptors, suggesting complex cellular networks in the SFO that may influence physiology. This research was supported by the National Institutes of Health and the American Heart Association. [Extracted from the article]

Researchers at the National University of Singapore have developed a personalized treatment approach for non-small cell lung cancer (NSCLC) by using custom-designed antisense oligonucleotides (ASOs) to target specific mutations in the epidermal growth factor receptor (EGFR) gene. This strategy aims to overcome drug-resistant mutations and reduce toxicities associated with standard tyrosine kinase inhibitors (TKIs). By delivering EGFR-targeting ASOs via extracellular vesicles (EVs), the researchers have demonstrated promising results in inhibiting tumor growth in NSCLC models with EGFR mutations. This study highlights the potential of ASOs as an effective therapeutic platform for NSCLC treatment. [Extracted from the article]

Researchers at Taipei Medical University have conducted a study on renal cell carcinoma (RCC), the leading cause of mortality in RCC patients. The study focused on the role of the enzyme ADAMTS1 in regulating RCC metastasis. The researchers found that elevated ADAMTS1 levels were correlated with a poor prognosis in RCC patients. They also discovered a cyclic axis involving ADAMTS1-VCAN-EGFR, which contributes to RCC invasion and resistance to anoikis. This finding presents a potential therapeutic target for RCC metastasis. [Extracted from the article]

A recent study conducted by researchers at the University of Wisconsin School of Medicine and Public Health explored the role of Bim expression in choroidal endothelial cells (ChECs) and its impact on choroidal neovascularization (CNV). The study found that ChECs lacking Bim expression exhibited increased expression of vascular endothelial growth factor (VEGF), osteopontin, and inflammatory cytokines, as well as enhanced proliferation and capillary morphogenesis. Additionally, the study revealed that treatment modalities that require the intrinsic death pathway, such as anti-VEGF, were less effective in mitigating CNV in mice lacking Bim expression. These findings suggest that Bim expression could influence the effectiveness of certain treatment approaches for CNV. [Extracted from the article]

A study conducted in Shanxi, People's Republic of China, examined the efficacy and safety of combining Apatinib with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance. The study analyzed the clinical records of 106 NSCLC patients, with 52 patients receiving Apatinib combined with EGFR-TKI and 54 patients receiving standard chemotherapy. The results showed that Apatinib combined with EGFR-TKI had similar efficacy to standard chemotherapy, but was associated with longer progression-free survival (PFS) and no significant increase in adverse reactions. [Extracted from the article]

Researchers at the University of Crete have conducted a study on receptor protein-tyrosine kinases, specifically focusing on the epidermal growth factor receptor (EGFR). The study aimed to synthesize and evaluate novel rhenium-based complexes incorporating EGFR tyrosine kinase inhibitors (TKIs) to enhance anticancer efficacy, particularly in radiosensitization. The researchers synthesized a rhenium tricarbonyl complex and its technetium-99m analog, which showed promising results in terms of cytotoxicity, EGFR inhibition, apoptosis induction, and radiosensitization. The study suggests that these complexes have potential as dual-function anticancer agents and should be further investigated in preclinical models. [Extracted from the article]

A recent study conducted by researchers at South China University of Technology has found that almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, may be an effective treatment for acute respiratory distress syndrome (ARDS) induced by EGFR-mutated non-small cell lung cancer (NSCLC). The study focused on a 63-year-old Chinese Han female with severe NSCLC complicated by ARDS. After being treated with almonertinib, the patient experienced significant clinical improvement and successful extubation after nine days. The findings suggest that almonertinib could be a viable therapeutic option for managing severe complications in NSCLC, although further research is needed to confirm these results and optimize dosage and toxicity management strategies. [Extracted from the article]

A recent report from Texas A&M University highlights the importance of early diagnosis for preeclampsia, a potentially life-threatening condition for pregnant women and their babies. The study focuses on the development and evaluation of aptamers, which are molecules that can bind to specific biomarkers associated with preeclampsia. The researchers found that these aptamers demonstrated strong binding affinities, comparable or superior to traditional antibodies. The findings suggest that these aptamers have the potential to be integrated into cost-effective, point-of-care diagnostic tools, improving early detection and intervention strategies for preeclampsia and ultimately leading to better maternal and fetal health outcomes. [Extracted from the article]

Researchers from the Medical University of Sofia in Bulgaria conducted a study on the effects of citric acid on stem cells from apical papillae (SCAPs). The study found that citric acid can promote the differentiation of SCAPs and angiogenesis, which is the formation of new blood vessels. The researchers observed different mineralization patterns and changes in the secretion of vascular endothelial growth factor (VEGF) in the cells treated with citric acid. This research provides valuable insights into the potential applications of citric acid in stem cell research. [Extracted from the article]

A recent study conducted at Tanta University in Egypt explored the effect of anti-vascular endothelial growth factor (VEGF) injection on neovascularization of the retina in cases of proliferative diabetic retinopathy (PDR). The study involved 30 patients diagnosed with PDR who received anti-VEGF injections for three months. The researchers found that the injections had a significant positive effect on neovascularization in the retina. The study concluded that anti-VEGF injections can be effective in treating neovascularization in PDR, not just macular edema. [Extracted from the article]

A recent report from Iasi, Romania discusses the treatment of age-related macular degeneration (AMD), a progressive eye disease that can lead to blindness. The main focus of treatment is to maintain and improve visual acuity by injecting anti-VEGF agents into the eye. The report highlights the importance of considering biomarkers such as subretinal and intraretinal fluids when determining the frequency of therapy. It also discusses the challenges of implementing guideline recommendations in real-life clinical practice and emphasizes the need to optimize treatment regimens for long-term follow-up. For more information, the full report can be accessed through the provided link. [Extracted from the article]

A new report from National Taiwan University Hospital presents fresh data on age-related macular degeneration (AMD). The study evaluates the impact of anti-vascular endothelial growth factor (anti-VEGF) treatment on neovascular AMD with and without pigment epithelial detachment (PED) over a one-year period. The retrospective analysis included 88 eyes treated with intravitreal aflibercept injections. The study found significant reductions in central macular thickness and PED height, although no statistical difference was found in best-corrected visual acuity. The presence or type of PED did not negatively impact visual outcomes. The study highlights the effectiveness of anti-VEGF therapy in real-world settings and offers insights into factors influencing visual outcomes for AMD patients with PED. [Extracted from the article]

Researchers at Chongqing University in China have published a study on the ultrasensitive detection of biomarkers using anisotropic gold nanorods and dark-field imaging. The study focuses on the detection of tumor markers in body fluids for cancer screening, diagnosis, and prognosis analysis. The researchers developed a method that combines a microfluidic chip and dark-field microscopy to achieve high sensitivity and a detection limit of 10 pg/mL for the biomarker Vascular Endothelial Growth Factor (VEGF). This method has the potential for early cancer diagnosis and prognosis analysis. [Extracted from the article]

A recent report from the University of Texas Health Science Center Houston explores the potential of epiregulin (EREG) and amphiregulin (AREG) as prognostic, predictive, and therapeutic targets in colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) plays a critical role in regulating cellular processes that promote cancer, and current EGFR-targeted therapies for metastatic CRC include cetuximab and panitumumab. However, resistance to these therapies is common, so additional biomarkers are needed to understand patient sensitivity. The report discusses the overexpression of EREG and AREG in CRC and their potential roles in tumor progression, as well as recent advances in therapeutic targeting through the use of targeted monoclonal antibodies and antibody-drug conjugates. The authors also address the challenges and strategies for implementing EREG and AREG as biomarkers. [Extracted from the article]

A study conducted at Jeonbuk National University in South Korea explored the use of computational methods to identify potential inhibitors for mutant forms of the epidermal growth factor receptor (EGFR), which is a promising target for treating non-small cell lung cancer (NSCLC). The researchers used virtual screening, molecular docking, and molecular dynamics simulations to identify five novel compounds that could be evaluated as single agents or in combination with existing therapies for the treatment of EGFR-mutant NSCLC. The study was funded by the National Research Foundation of Korea and the Technology Innovation Program. [Extracted from the article]

A study conducted by researchers at Tehran University of Medical Sciences compared the effects of two treatments, pan-retinal photocoagulation (PRP) and intravitreal bevacizumab (IVB), on macular vascular changes in patients with severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy. The study found that both treatments were able to normalize or stabilize vascular measures over time, although they had different short-term macular vascular responses. The researchers used optical coherence tomography angiography (OCTA) to measure foveal avascular zone (FAZ) characteristics and the densities of superficial and deep capillary plexuses (SCP and DCP). The findings suggest that both PRP and IVB are effective treatments for these conditions. [Extracted from the article]

A study conducted in Vila Nova de Gaia, Portugal aimed to identify predictive factors for the improvement of visual acuity and reduction of central macular thickness in patients with macular edema due to branch retinal vein occlusion. The study included 161 eyes and found that visual acuity significantly improved and central macular thickness decreased during the 12-month follow-up period. Age at diagnosis and baseline visual acuity were identified as independent predictors of visual outcome. The study provides valuable information for the treatment of macular edema in patients with branch retinal vein occlusion. [Extracted from the article]

A recent study conducted at the University of Jinan in Guangdong, China, explored the role of fucosyltransferase-6 (FUT6) in esophageal cancer (ESCA). The researchers found that FUT6 was downregulated in ESCA cells and that its overexpression suppressed cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in ESCA cells. Additionally, FUT6 was found to suppress the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) signaling pathway, which is involved in ESCA progression. These findings suggest that FUT6 may have potential as a therapeutic target for ESCA. [Extracted from the article]

A researcher from Hangzhou Dianzi University in China has published findings on telemedicine in the field of ophthalmology. The study focuses on the accurate prediction of visual acuity (VA) in patients with diabetic macular edema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The researcher proposes a multimodal algorithm that combines optical coherence tomography (OCT) images and clinical data to predict VA values. The model performed well in a telemedicine competition, achieving high accuracy in retinal segmentation and VA prediction. This research has implications for improving treatment outcomes for DME patients in telemedicine settings. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the role of insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (IR) in LepRb neurons in regulating body growth, bone mass, reproduction, and metabolism. The study found that IGF1R and IR in LepRb neurons are necessary for normal pubertal onset and adult fertility, as well as for maintaining bone mass. Additionally, the deletion of IGF1R and IR in LepRb neurons resulted in increased fat mass, decreased lean mass, lower energy expenditure, and impaired insulin sensitivity. These findings highlight the complex roles of IGF1R and IR in LepRb neurons in regulating various physiological processes. [Extracted from the article]

A study conducted at the University of Life Sciences in Lublin, Poland examined the concentrations of vascular endothelial growth factor A (VEGF-A) in canine malignant mammary gland tumors. The study found that the mean concentration of VEGF-A in the malignant tumors, both with and without metastases to regional lymph nodes, was significantly higher than in normal mammary glands. Additionally, the concentration of VEGF-A was higher in tumors with metastases compared to non-metastatic tumors. These findings suggest that increased production of VEGF-A may play a role in the malignancy and metastasis of canine mammary tumors. [Extracted from the article]

A recent study conducted by researchers at the Second Hospital of Hebei Medical University in China explores the relationship between gut microbiota, stroke, and angiogenesis in older adults. The study found that older stroke patients had reduced gut microbiota diversity compared to younger stroke patients. Additionally, levels of acetate, a short-chain fatty acid produced by gut bacteria, were lower in older stroke patients and positively correlated with angiogenesis markers. Transplanting gut microbiota from younger donors into aged mice improved stroke outcomes by promoting angiogenesis, facilitated by lymphatic ingrowth into the cortex. The study suggests that promoting acetate-producing bacteria in the gut could be a promising therapeutic strategy for reducing functional impairments in older stroke patients. [Extracted from the article]

A recent study conducted at Thammasat University in Pathum Thani, Thailand, focused on the development of thermoresponsive quercetin nanoemulgels (T-QNE-Gs) for intravitreal injection. The researchers aimed to optimize the formulation of these nanoemulgels and examine their inhibitory activity on vascular endothelial growth factor-A (VEGF-A) inducing neovascularization from retinal pigment endothelial cells. The study found that the T-QNE-Gs effectively inhibited migration and tube formation of human umbilical vein endothelial cells and suppressed VEGF-A gene expression and protein levels in retinal pigment epithelial cells. The researchers concluded that the T-QNE-Gs have potential for the treatment of vasoproliferative retinopathies and should be further investigated in animal models. [Extracted from the article]

Researchers from the Department of Gastroenterology in Zhejiang, China, have conducted a study on the efficacy of lenvatinib, a multi-target tyrosine kinase inhibitor, in treating gastric cancer. The study found that lenvatinib demonstrated significant inhibitory effects on the viability, proliferation, and metastatic capabilities of gastric cancer cells. The researchers identified platelet-derived growth factor receptor beta (PDGFRB) as a crucial target of lenvatinib, with its downregulation showing promise in enhancing overall survival rates of patients with gastric cancer. The study suggests that lenvatinib could be a promising therapeutic option for the treatment of gastric cancer. [Extracted from the article]

A clinical trial, NCT06605560, is currently recruiting participants to investigate the effectiveness of ultrasound-guided Baker cyst aspiration combined with platelet-rich plasma (PRP) injection in treating knee osteoarthritis. Baker cysts are common in patients with knee osteoarthritis and previous studies have used aspiration or corticosteroid treatment, but there is no research on the efficacy of PRP injection. The trial aims to compare the effectiveness of cyst aspiration and PRP injection on pain, function, and cyst size. The trial is expected to be completed by November 2025 and contact information for the primary investigator is provided. [Extracted from the article]

A recent study conducted by the University of Utah explored the potential benefits of targeting vascular endothelial growth factor B (VEGF-B) in patients with type 2 diabetes mellitus and diabetic kidney disease (DKD). The study involved a randomized controlled trial of CSL346, a humanized monoclonal antibody that binds to VEGF-B. However, the results showed that CSL346 did not significantly reduce urinary albumin-creatinine ratio (UACR) compared to a placebo after 16 weeks. Additionally, CSL346 was associated with an increase in diastolic blood pressure. Further research is needed to explore alternative treatments for DKD in patients with type 2 diabetes. [Extracted from the article]

A recent study conducted by researchers at the Federal Rural University of Pernambuco in Recife, Brazil, explores the potential benefits of melatonin therapy in the healing of diabetic wounds. The study investigates the effects of a combined treatment involving a bacterial cellulose dressing and melatonin application on the regulation and expression of inflammatory cytokines, VEGF, PCNA, and collagen in the healing of cutaneous wounds in diabetic rats. The results suggest that this combination therapy may have positive effects in regulating the expression of inflammatory cytokines, vascular endothelial growth factor, and collagen, making it a potential viable approach to wound healing in diabetic patients. [Extracted from the article]

A recent study from Tongji University investigated the role of connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) in the protein profile of the aqueous humor in patients with proliferative diabetic retinopathy (PDR) following intravitreal injection of conbercept. The study found that intravitreal conbercept effectively reduced VEGF levels while increasing CTGF levels, thereby modifying the CTGF/VEGF ratio. Proteomic analysis revealed that these changes were associated with critical biological pathways and protein interactions involved in immune response, stress response, and cellular metabolism. This research provides valuable insights into the effects of intravitreal conbercept on the protein profile of patients with PDR. [Extracted from the article]

Researchers from Columbia University have made new findings in receptor protein-tyrosine kinases, specifically related to vascular endothelial growth factor A (VEGF-A) and its role in promoting venous endothelial cell proliferation. The study focused on demyelinating acute and chronic lesions in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), which are characterized by leaky vessels and blood-brain barrier (BBB) damage. The research found that VEGF-A contributes to the formation of leaky vessels around these lesions, but blocking VEGF-A does not restore BBB function or ameliorate EAE pathology. These findings provide insights into the role of venous endothelial cells in neoangiogenesis during neuroinflammation. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine explores the potential benefits of inhibiting insulin-like growth factor-1 receptor/insulin receptor (IGF-1/IR) signaling in the treatment of obesity-associated esophageal adenocarcinoma (EAC). The researchers examined the effects of a small-molecule inhibitor called BMS-754807 in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) on EAC cells in vitro and in vivo. The results showed that the combination therapy produced greater antitumor effects, including increased apoptosis and improved survival rates in mice, compared to monotherapy with either BMS-754807 or nab-paclitaxel alone. These findings suggest that BMS-754807, either alone or in combination with nab-paclitaxel, could be a promising treatment option for EAC. [Extracted from the article]

A study conducted at the Third Military Medical University in Chongqing, China, has investigated the resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small cell lung cancer (NSCLC) patients. The researchers used RNA sequencing and bioinformatics analysis to identify two hub genes, myelocytomatosis oncogene (Myc) and axis inhibition protein 1 (Axin1), that were upregulated in osimertinib-resistant cell lines. They found that AXIN1 upregulated the expression of C-MYC and mediated the acquired resistance of EGFR mutant NSCLC cells to osimertinib. The study suggests that targeting the AXIN1/MYC signaling pathway could be a potential strategy for overcoming acquired resistance to osimertinib. [Extracted from the article]

A recent study conducted by researchers at Shandong First Medical University and Shandong Academy of Medical Sciences in China has explored the potential of a flavanone called Kurarinol (KUR) in treating non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). The study found that KUR effectively reduced lipid deposition and inflammation in hepatocytes, inhibited the proliferation of HCC cell lines, and suppressed NAFLD-HCC formation in mice. These effects were attributed to the suppression of epidermal growth factor receptor (EGFR) signaling. The findings suggest that KUR may be a promising strategy for preventing NAFLD-HCC through EGFR signaling suppression. [Extracted from the article]

A study conducted in Maharashtra, India, focuses on the treatment of non-small cell lung cancer (NSCLC) through targeted inhibition of the epidermal growth factor receptor (EGFR) and its mutants. The researchers designed and synthesized novel indole-thiazole derivatives as reversible EGFR inhibitors with minimal toxicity. The compounds showed potential as anticancer agents, with selectivity towards cancer cells and minimal toxicity towards normal cells. The study suggests that these compounds can specifically target mutant EGFR and may open new avenues for cancer therapy. [Extracted from the article]

A recent study conducted by the All India Institute of Medical Sciences (AIIMS) explored the potential of using plasma Epstein-Barr virus (EBV) DNA load, interleukin-6 (IL-6), and vascular endothelial growth factor (VEGF) levels as serological markers for early detection and prediction of treatment response in patients with nasopharyngeal carcinoma (NPC). The researchers found a positive correlation between high plasma EBV DNA load and higher IL-6 and VEGF expression, which was closely associated with therapeutic response. The study suggests that persistent or recurrent plasma EBV load with higher IL-6 and VEGF levels could potentially predict disease progression and aid in selecting patients for additional therapy and longer follow-up. [Extracted from the article]

A recent study conducted by researchers at the Ministry of Health in St. Petersburg, Russia, has found that patients with certain genetic mutations in lung cancer may not respond well to epidermal growth factor receptor (EGFR) inhibitors. The study suggests that patients with EGFR exon 19 deletions, wild-type TP53, good performance status, low tumor burden, and no circulating tumor DNA (ctDNA) at baseline are more likely to benefit from EGFR inhibitor therapy. On the other hand, patients with EGFR L858R substitutions, mutated TP53, poor overall condition, high tumor volume, and detectable ctDNA are generally poor responders to EGFR inhibitors. The researchers recommend that these patients be considered for clinical trials involving the addition of chemotherapy and antiangiogenic drugs. [Extracted from the article]

A recent report from Teikyo University School of Medicine in Tokyo, Japan discusses the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as targeted therapy for lung cancer. The researchers developed a new immunocytology-based platform for detecting circulating tumor cells (CTCs) and analyzing EGFR mutations in lung cancer patients. The study found that CTC levels were significantly higher in pulmonary arterial blood and pulmonary venous blood compared to peripheral blood. The platform showed promise as a convenient method for detecting CTC number and EGFR mutation status, suggesting its potential as a liquid biopsy tool for lung cancer patients. [Extracted from the article]

The patent application titled "Rpe Cell Populations And Methods Of Generating Same" provides detailed information on a method for generating retinal pigment epithelium (RPE) cells from pluripotent stem cells. These RPE cells have specific characteristics and functions, such as the secretion of certain proteins and the ability to improve visual acuity in animal models. The invention also includes the use of these cells in drug discovery, cell therapy, and treating retinal degeneration. The patent application offers valuable insights into the differentiation process and the properties of the generated RPE cells. [Extracted from the article]

A recent survey conducted by researchers at the Department of Ophthalmology in South Brisbane, Australia, examined the preferred treatment patterns for retinopathy of prematurity (ROP) and trends in the use of anti-vascular endothelial growth factor (VEGF) for ROP. The survey included responses from 54 ophthalmologists from 11 different countries. The findings revealed that anti-VEGF was the preferred treatment method for aggressive ROP and Type 1 ROP in zone 1 and posterior zone 2, while laser was the preferred treatment for Type 1 ROP in anterior zone 2 and zone 3. The study also found that the use of anti-VEGF as a first-line therapy has been increasing. [Extracted from the article]

A study conducted in Nanjing, China, evaluated the efficacy and safety of combining epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with Shenqi Fuzheng injection (SFI) in patients with advanced non-small cell lung cancer (NSCLC) and EGFR-sensitive mutations. The study included 88 patients who received either EGFR-TKIs alone or in combination with SFI as first-line targeted treatment. The combination therapy group showed a longer median progression-free survival (PFS) and lower incidence of adverse reactions compared to the monotherapy group. The researchers concluded that SFI combined with EGFR-TKIs is more effective and better tolerated in patients with advanced NSCLC and EGFR-sensitive mutations. [Extracted from the article]